Zhaohong Chen

Deyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.

Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.

Journal: Cancer communications (London, England)

Published: November 29, 2025

Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.

Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 09, 2025

Bilateral breast metastases from rectal malignant melanoma: case report and literature review.

Bilateral breast metastases from rectal malignant melanoma: case report and literature review.

Journal: Frontiers in oncology

Published: January 23, 2025

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.

Journal: The Lancet. Respiratory medicine

Published: August 11, 2024

Case Report: Intensity-modulated radiotherapy combined with immunotherapy for intramedullary spinal cord metastases of lung adenocarcinoma.

Case Report: Intensity-modulated radiotherapy combined with immunotherapy for intramedullary spinal cord metastases of lung adenocarcinoma.

Journal: Frontiers in oncology

Published: January 08, 2024

PPFIA4 Promotes Proliferation, Migration and Glycolysis of Esophageal Cancer Cells.

PPFIA4 Promotes Proliferation, Migration and Glycolysis of Esophageal Cancer Cells.

Journal: Annals of clinical and laboratory science

Published: January 05, 2024

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 22, 2023

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 05, 2022

Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer.

Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer.

Journal: Oncology letters

Published: August 25, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026